Technical Analysis for NBIX - Neurocrine Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
86.1 | -4.15% | -3.73 |
NBIX closed up 5.89 percent on Thursday, March 21, 2019, on 1.5 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| See historical NBIX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 21 | New Uptrend | Bullish | -4.15% |
| Mar 21 | 180 Bullish Setup | Bullish Swing Setup | -4.15% |
| Mar 21 | Pocket Pivot | Bullish Swing Setup | -4.15% |
| Mar 21 | Upper Bollinger Band Walk | Strength | -4.15% |
| Mar 21 | Multiple of Ten Bearish | Other | -4.15% |
| Mar 21 | Weak + Overbought | Other | -4.15% |
| Mar 21 | Above Upper BB | Strength | -4.15% |
| Mar 21 | Overbought Stochastic | Strength | -4.15% |
| Mar 21 | Upper Bollinger Band Touch | Strength | -4.15% |
| Mar 20 | Stochastic Sell Signal | Bearish | 1.50% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-05-01
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Chemistry Pain Diabetes Disorders Schizophrenia Alcohols Cardiovascular Diseases Hormones Epilepsy Ethers Movement Disorders Ii Diabetes Pyrimidines Gnrh Antagonists Insomnia Endometriosis Gonadotropin Releasing Hormone Antagonist Uterine Fibroids
Chemistry Pain Diabetes Disorders Schizophrenia Alcohols Cardiovascular Diseases Hormones Epilepsy Ethers Movement Disorders Ii Diabetes Pyrimidines Gnrh Antagonists Insomnia Endometriosis Gonadotropin Releasing Hormone Antagonist Uterine Fibroids
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more NBIX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 126.98 |
| 52 Week Low | 64.72 |
| Average Volume | 917,915 |
| 200-Day Moving Average | 98.3635 |
| 50-Day Moving Average | 84.0448 |
| 20-Day Moving Average | 81.075 |
| 10-Day Moving Average | 83.623 |
| Average True Range | 2.9396 |
| ADX | 25.1 |
| +DI | 30.6556 |
| -DI | 14.25 |
| Chandelier Exit (Long, 3 ATRs ) | 81.6612 |
| Chandelier Exit (Short, 3 ATRs ) | 83.5188 |
| Upper Bollinger Band | 88.6151 |
| Lower Bollinger Band | 73.5349 |
| Percent B (%b) | 1.08 |
| BandWidth | 18.600308 |
| MACD Line | 1.2078 |
| MACD Signal Line | -0.0222 |
| MACD Histogram | 1.23 |
| Fundamentals | Value |
|---|---|
| Market Cap | 7.92 Billion |
| Num Shares | 88.2 Million |
| EPS | -2.52 |
| Price-to-Earnings (P/E) Ratio | -35.65 |
| Price-to-Sales | 826.51 |
| Price-to-Book | 15.16 |
| PEG Ratio | 1.78 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 96.00 | ||||
| Resistance 3 (R3) | 95.53 | 93.00 | 94.97 | ||
| Resistance 2 (R2) | 93.00 | 91.43 | 93.24 | 94.62 | |
| Resistance 1 (R1) | 91.42 | 90.46 | 92.21 | 91.89 | 94.28 |
| Pivot Point | 88.89 | 88.89 | 89.29 | 89.13 | 88.89 |
| Support 1 (S1) | 87.31 | 87.32 | 88.10 | 87.78 | 85.38 |
| Support 2 (S2) | 84.78 | 86.35 | 85.02 | 85.04 | |
| Support 3 (S3) | 83.20 | 84.78 | 84.69 | ||
| Support 4 (S4) | 83.67 |
